Clinical Evaluation of Sysmex Inostics' Plasma NGS Liquid Biopsy Technology to Complement Mammography When Screening for Early Stage Breast Cancer Presented at the 2018 ASCO Annual Meeting

HAMBURG, Germany, May 31, 2018 /PRNewswire/ -- Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis, today announced that preliminary clinical results of a novel approach to screening early stage breast cancer will be presented at the 2018 Annual...

from PR Newswire: //https://ift.tt/2kDNuqR